Vivos Therapeutics Plans Rights Offering to Existing Shareholders
I'm LongbridgeAI, I can summarize articles.Vivos Therapeutics (VVOS) announced plans for a rights offering to existing shareholders, aiming to raise capital for operations. The offering involves transferable subscription rights exercisable over nine months at strike prices tied to market value. Proceeds are for general corporate purposes, contingent on SEC approval and shareholder consent. Analyst ratings vary, with TipRanks AI labeling VVOS as Neutral due to weak financials despite revenue growth.
Vivos Therapeutics ( (VVOS) ) has shared an update.
On June 11, 2026, Vivos Therapeutics announced plans to file a registration statement with the U.S. Securities and Exchange Commission for a proposed rights offering that would distribute transferable subscription rights to existing shareholders as a dividend. Each preliminary right is expected to allow holders to buy one share of common stock at the greater of $1.25 or 20% above the market price before the record date, with the rights listed for trading and exercisable over nine months.
Investors who exercise these rights are expected to receive an additional nine‑month trading right with a higher strike price set at the greater of $1.75 or 40% above the pre‑record‑date market price, though all terms remain subject to change and finalization in a prospectus. The offering, aimed at raising additional capital for operations and general corporate purposes, is contingent on SEC effectiveness, exchange listing and shareholder approvals, and may be modified, delayed or terminated depending on market conditions and corporate and regulatory constraints.
The most recent analyst rating on (VVOS) stock is a Buy
with a $3.00 price target.
To see the full list of analyst forecasts on Vivos Therapeutics stock,
see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
The score is held down primarily by weak financial quality (large losses, heavy cash burn, and negative equity) and ongoing financing/listing-risk signals. Strong revenue growth and improving gross margin provide some support, but technicals remain weak longer term and valuation is not compelling given continued unprofitability and no dividend.
To see Spark’s full report on VVOS stock,
click here.
More about Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on diagnostic and treatment solutions for breathing-related sleep disorders such as obstructive sleep apnea and snoring in adults and children. Based in Littleton, Colorado, it markets FDA-cleared Complete Airway Repositioning and Expansion devices and the Vivos Method through collaborations with sleep healthcare providers.
The company targets a large, underdiagnosed global OSA population, positioning itself as an alternative to legacy treatments like CPAP by offering nonsurgical, noninvasive and nonpharmaceutical therapies. Its strategy combines innovative medical devices, education initiatives and strategic partnerships or acquisitions to expand its presence in the sleep-health market.
Average Trading Volume: 1,440,432
Technical Sentiment Signal: Sell
Current Market Cap: $7.95M
Learn more about VVOS stock on TipRanks’ Stock Analysis page.